Our data suggest that NLRP3 activation through LPS/Nigericin treatment leads to a high level of IL-1β and IL-18 secretion in prostate cancer and glioblastoma cell lines compared to cell lines derived from lung cancer, breast cancer, and neuroblastoma. This evidence concerns the gene NLRP3 and prostate carcinoma.